Keisuke Koroki
Overview
Explore the profile of Keisuke Koroki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qiang N, Ao J, Nakamura M, Katayama K, Zhang J, Kogure T, et al.
Biochem Pharmacol
. 2025 Feb;
235:116829.
PMID: 40015652
Lenvatinib (LEN)-treated patients with hepatocellular carcinoma (HCC) are frequently accompanied by skeletal muscle loss, which is correlated with poor prognosis. Interactions between tumor and skeletal muscle may play a role...
2.
Miwa C, Ogasawara S, Yonemoto T, Yumita S, Okubo T, Nakagawa M, et al.
Cancer Med
. 2025 Feb;
14(5):e70642.
PMID: 40013724
Aim: Combination immunotherapy is the standard of care for advanced hepatocellular carcinoma (HCC). However, some patients are unsuitable for such treatment. This study investigated the safety and effectiveness of durvalumab...
3.
Ao J, Qiang N, Kanzaki H, Nakamura M, Kakiuchi R, Zhang J, et al.
Am J Physiol Cell Physiol
. 2024 Sep;
327(4):C1150-C1161.
PMID: 39250819
In the era of immunotherapy, lenvatinib (LEN) still holds an important position in the sequential treatment of advanced hepatocellular carcinoma (HCC). However, the sustained therapeutic effect of LEN is not...
4.
Ozaki T, Yumita S, Ogasawara S, Fujiya M, Tsuchiya T, Yoshino R, et al.
Hepatol Res
. 2024 Jun;
PMID: 38943555
Cytokine release syndrome (CRS) is a systemic inflammatory syndrome that causes fatal circulatory failure due to hypercytokinemia, and subsequent immune cell hyperactivation caused by therapeutic agents, pathogens, cancers, and autoimmune...
5.
Kobayashi K, Ogasawara S, Itobayashi E, Okubo T, Itokawa N, Nakamura K, et al.
Invest New Drugs
. 2024 Jun;
42(4):394-404.
PMID: 38842657
This study aimed to complement the results of the REACH-2 study by prospectively evaluating the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma (HCC) in a real-world setting. This...
6.
Fujiwara K, Kondo T, Fujimoto K, Yumita S, Ogawa K, Ishino T, et al.
J Gastroenterol
. 2024 Apr;
59(6):515-525.
PMID: 38583112
Background: During systemic therapy, the management of portal hypertension (PH)-related complications is vital. This study aimed to clarify factors associated with the incidence and exacerbation of PH-related complications, including the...
7.
Yoshida R, Koroki K, Makishima H, Ogasawara S, Ishino T, Ogawa K, et al.
Case Rep Oncol
. 2023 Dec;
14(2):1103-1110.
PMID: 38075390
Macrovascular invasion (MVI), including portal vein tumor thrombosis (PVTT), is strongly associated with poor prognosis in patients with hepatocellular carcinoma (HCC). While recommended standard treatment for patients with advanced HCC...
8.
Kobayashi K, Ogasawara S, Maruta S, Okubo T, Itokawa N, Haga Y, et al.
Clin Cancer Res
. 2023 Oct;
29(23):4760-4769.
PMID: 37796614
Purpose: This study aimed to investigate the safety and efficacy of lenvatinib in real-world settings, including patients excluded from the REFLECT trial, a phase III trial that compared lenvatinib with...
9.
Kondo T, Fujimoto K, Fujiwara K, Yumita S, Ishino T, Ogawa K, et al.
Sci Rep
. 2023 Aug;
13(1):14043.
PMID: 37640752
The pathogenesis of acute liver failure (ALF) involves cell death. Necroptosis is a newly suggested programmed cell death, and receptor-interacting protein kinase 3 (RIPK3) has been reported as a marker...
10.
Kanzaki H, Ogasawara S, Okubo T, Itokawa N, Yoshino R, Fujimoto K, et al.
Drugs Real World Outcomes
. 2023 Jul;
10(4):513-520.
PMID: 37466822
Background: Cabozantinib was found to be effective as a second- or third-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) in the phase 3 CELESTIAL trial. So far,...